Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models ; volume:4 ; number:1 ; day:8 ; month:3 ; year:2016 ; pages:1-12 ; date:12.2016
Acta Neuropathologica Communications ; 4, Heft 1 (8.3.2016), 1-12, 12.2016
- Urheber
-
Reinert, Jochim
- Beteiligte Personen und Organisationen
-
Richard, Bernhard C.
Klafki, Hans W.
Friedrich, Beate
Bayer, Thomas A.
Wiltfang, Jens
Kovacs, Gabor G.
Ingelsson, Martin
Lannfelt, Lars
Paetau, Anders
Bergquist, Jonas
Wirths, Oliver
SpringerLink (Online service)
- DOI
-
10.1186/s40478-016-0294-7
- URN
-
urn:nbn:de:1111-2016031518508
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reinert, Jochim
- Richard, Bernhard C.
- Klafki, Hans W.
- Friedrich, Beate
- Bayer, Thomas A.
- Wiltfang, Jens
- Kovacs, Gabor G.
- Ingelsson, Martin
- Lannfelt, Lars
- Paetau, Anders
- Bergquist, Jonas
- Wirths, Oliver
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Eisregen, [...]. [Partitur]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Eisregen, [...]. [Partitur]
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
Computergestütztes Screening kognitiver Beeinträchtigungen - Ergebnisse einer Validierungsstudie zum Programm „Kopfsache Interaktiv”
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
Eisregen, [...]. [Partitur]
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
Computergestütztes Screening kognitiver Beeinträchtigungen - Ergebnisse einer Validierungsstudie zum Programm „Kopfsache Interaktiv”
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
Eisregen, [...]. [Partitur]
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
Computergestütztes Screening kognitiver Beeinträchtigungen - Ergebnisse einer Validierungsstudie zum Programm „Kopfsache Interaktiv”
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.